Marks Group Wealth Management’s Ascendis Pharma A/S ASND Stock Holding History

Marks Group Wealth Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16M	Buy	4,345 +407	+10%	+$95.1K	0.1%	190
2026 Q1	$901K	Buy	+3,938	New	+$883K	0.09%	201

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Marks Group Wealth Management's ASND Position: Q2 2026 in Review

Marks Group Wealth Management increased its Ascendis Pharma A/S (ASND) stake by 10% in Q2 2026, buying an estimated $95.1K and bringing the position to 4,345 shares worth $1.16M. The position accounts for 0.1% of the portfolio, ranked #190.

Marks Group Wealth Management first reported a position in ASND in Q1 2026 and has held it in 2 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Marks Group Wealth Management held 4,345 shares of Ascendis Pharma A/S worth $1.16M as of Q2 2026.
Marks Group Wealth Management bought 407 Ascendis Pharma A/S shares in Q2 2026, an estimated $95.1K.
Ascendis Pharma A/S made up 0.1% of Marks Group Wealth Management's portfolio in Q2 2026, its #190 holding.
Marks Group Wealth Management first reported a position in Ascendis Pharma A/S in Q1 2026 and has held it in 2 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.